Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker